Chronic Lymphocytic Leukemia — Microlearning Activity 1

Listen in the Podli app 🎧

Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)
Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)
Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)